人促甲状腺激素受体及其抗体与Graves病关系研究进展

王冉; 张晓梅

人促甲状腺激素受体及其抗体与Graves病关系研究进展

王冉,
张晓梅

1.
蚌埠医学院第一附属医院内分泌科, 安徽蚌埠 233004

作者简介: 王冉(1982－ ),女,硕士研究生.

基金项目:

摘要: Graves病(Graves disease,GD)是一种器官特异性自身免疫病,与桥本甲状腺炎(HT)同属自身免疫性甲状腺疾病(AITD),在西方人群的发病率为0.5%～1.0%[1],在中国人群中为0.25%～1.09%[2]。
- Graves病 /
- 促甲状腺素受体 /
- 促甲状腺激素受体抗体 /
- 自身免疫性甲状腺病 /
- 综述

[1]	Chistyakov DA,Savost' anov KV,Turakulov RI,et al.Genetic determinants of Graves disease[J].Mol Genet Metab,2000,71(1/2):66-69.
[2] 张珍,林益川,方志平,等.食盐加碘 10 年对地方性甲状腺肿和甲状腺功能亢进症患病率的影响[J].中华内分泌代谢杂志,2000,18(5):342-344.
[3] Jacobson EM,Tomer Y.The CD40,CTLA-4,thyroglobulin,TSH receptor,and PTPN22 gene quintet and its contribution to thyroidautoimmunity:back to the future[J].J Autoimmun,2007,28(2/3):85-98.
[4] Dechairo BM,Zabaneh D,Collins J,et al.Association of the TSHR gene with Graves' disease:the first disease specific locus[J].Eur J Hum Genet,2005,13(11):1223-1230.
[5] Frazier AL,Robbins LS,Stork PJ,et al.Isolation of TSH and LH/CG receptor cDNAs from human thyroid:regulation by tissue specific splicing[J].Mol Endocrinol,1990,4(8):1264-1276.
[6] Kakinuma A,Nagayama Y.Multiple messenger ribonucleic acid transcripts and revised gene organization of the human TSH receptor[J].Endocr J,2002,49(2):175-180.
[7] Hunt N,Willey KP,Abend N,et al.Novel splicing variants of the human thyrotropin receptor encode truncated polypeptides without a membrane-spanning domain[J].Endocrine,1995,3 ( 3 ):233-240.
[8] Rapoport B,Chazenbalk GD,Jaume JC,et al.The thyrotropin (TSH) receptor:interaction with TSH and autoantibodies[J].Endocr Rev,1998,19(6):673-716.
[9] Vassart G,Costagliola S.A physiological role for the posttranslational cleavage of the thyrotropin receptor[J].Endocrinology,2004,145(1):1-3.
[10] Ciullo I,Latif R,Graves P,et al.Functional assessment of the thyrotropin receptor-beta subunit [J].Endocrinology,2003,144(7):3176-3181.
[11] Chen CR,Pichurin P,Nagayama Y,et al.The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim[J].J Clin Invest,2003,111(12):1897-1904.
[12] Pichurin PN,Chen CR,Chazenbalk GD,et al.Targeted expression of the human thyrotropin receptor A-subunit to the mouse thyroid:insight into overcoming the lack of response to A-subunit adenovirus immunization [J].J Immunol,2006,176 ( 1 ):668-676.
[13] Davies TF,Ando T,Lin RY,et al.Thyrotropin receptor-associated diseases:from adenomata to Graves disease[J].J Clin Invest,2005,115(8):1972-1983.
[14] Tonacchera M,Pinchera A.Thyrotrophin receptor polymorphisms and thyroid disease[J].J Clin Endocrinol Metab,2000,85(8):2637-2639.
[15] Dechairo BM,Zabaneh D,Collins J,et al.Association of the TSHR gene with Graves' disease:the first disease specific locus[J].Eur J Hum Genet,2005,13(11):1223-1230.
[16] Chistiakov DA,Savost' anov KV,Turakulov RI,et al.Further studies of genetic susceptibility to Graves' disease in a Russian population[J].Med Sci Monit,2002,8(3):CR180- CR184.
[17] Ban Y,Greenberg DA,Concepcion ES,et al.A germline single nucleotide polymorphism at the intracellular domain of the human thyrotropin receptor does not have a major effect on the development of Graves' disease[J].Thyroid,2002,12 (12):1079-1083.
[18] Burton PR,Clayton DG,Cardon LR,et al.Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants[J].Nat Genet,2007,39(11):1329-1337.
[19] Hiratani H,Bowden DW,Ikegami S,et al.Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves' disease[J].J Clin Endocrinol Metab,2005,90(5):2898-2903.
[20] Ho SC,Goh SS,Khoo DH.Association of Graves' disease with intragenic polymorphism of the thyrotropin receptor gene in a cohort of Singapore patients of multi-ethnic origins[J].Thyroid,2003,13(6):523-528.
[21] Yin X,Latif R,Bahn R,et al.Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy[J].Thyroid,2008,18(11):1201-1206.
[22] Brand OJ,Barrett JC,Simmonds MJ,et al.Association of the thyroid stimulating hormone receptor gene(TSHR) with Graves' disease[J].Hum Mol Genet,2009,18(9):1704-1713.
[23] Ploski R,Brand OJ,Jurecka-Lubieniecka B,et al.Thyroid stimulating hormone receptor(TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts[J].PLoS One,2010,5(11):e15512.
[24] 梁军,赵家军,高聆,等.TSH 受体基因 SNP 与 Graves 病、桥本甲状腺炎和结节性甲状腺肿之间的相关性研究[J].中华内分泌代谢杂志,2004,20(6):510-513.
[25] Gu LQ,Zhu W,Zhao SX,et al.Clinical associations of the genetic variants of CTLA-4,Tg,TSHR,PTPN22,PTPN12 and FCRL3 in patients with Graves' disease[J].Clin Endocrinol(Oxf),2010,72(2):248-255.
[26] Ye F,Hou P,Wu X,et al.The significance of immune-related molecule expression profiles in an animal model of Graves' disease[J].Autoimmunity,2011,45(2):143-152.
[27] Sibarani RP.Genetics of Graves' disease:the lost concept[J].Acta Med Indones,2009,41(1):37-40.
[28] Jeffreys J,Depraetere H,Sanders J,et al.Characterization of thyrotropin binding pocket [J].Thyroid,2002,12 ( 12 ):1051-1061.
[29] Wallaschofski H,Miehle K,Mayer A,et al.Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating,blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment[J].Horm Metab Res,2002,34(7):383-388.
[30] Wiersinga WM,Prummel MF.Pathogenesis of Graves'ophthalmopathy-current understanding[J].J Clin Endocrinol Metab,2000,86(2):501-503.
[31] Davies TF,Roti E,Braverman LE,et al.Thyroid controversy-stimulating antibodies[J].J Clin Endocrinol Metab,1998,83(11):3777-3785.
[32] Saravanan P,Dayan CM.Thyroid autoantibodies[J].Endocrinol Metab Clin North Am,2001,30(2):315-337.
[33] Menndez Torre E,Anda Apianiz E,Barberia Layana JJ,et al.Recurrence and prognostic factors after treatment with antithyroid agents in Graves-Basedow disease.Multicenter study in Northern Spain[J].Rev Clin Exp,2000,200(2):69-73.
[34] Metso S,Jaatinen P,Huhtala H,et al.Long-term follow-up study of radioiodine treatment of hyperthyroidism[J].Clin Endocrinol,2004,61(5):641-648.
[35] Cappelli C,Gandossi E,Castellano M,et al.Prognostic value of thyrotropin receptor antibodies ( TRAb) in Graves' disease:a 120 months prospective study[J].Endocr J,2007,54 (5 ):713-720.
[36] 缪婕,赵咏桔,王曙,等.Graves 病患者药物治疗复发的相关因素分析[J].中华内科杂志,2008,47(3):185-188.
[37] Chiapppori A,Villalta D,Bossert I,et al.Thyrotropin receptor autoantibody measurement following radiometabolic treatment of hyperthyroidism:comparison between different methods[J].J Endocrinol Invest,2010,33(3):197-201.
[38] Paunkovic J,Paunkovic N.Does autoantibody-negative Graves' disease exist? A second evaluation of the clinical diagnosis[J].Horm Metab Res,2006,38(1):53-56.
[39] Laurberg P,Bournaud C,Karmisholt J,et al.Management of Graves' hyperthyroidism in pregnancy:focus on both maternal and foetal thyroid function,and caution against surgical thyroidectomy in pregnancy[J].Eur J Endocrinol,2009,160(1):1-8.
[40] Laurberg P,Nygaard B,Glinoer D,et al.Guidelines for TSH-receptor antibody measurements in pregnancy:results of an evidence-based symposium organized by the European Thyroid Association[J].Eur J Endocrinol,1998,139(6):584-586.

[1]	吴晨辰 , 张晓梅 , 孙卫华 , 王冉 , 赵文娣 , 刘田 . 汉族人群促甲状腺素受体基因内含子1区域多态性与Graves病及临床表现的关系. 蚌埠医学院学报, 2016, 41(11): 1405-1407,1412. doi: 10.13898/j.cnki.issn.1000-2200.2016.11.002
[2]	滕晓蕾 , 张晓梅 . 单核苷酸多态性与自身免疫性甲状腺疾病研究进展. 蚌埠医学院学报, 2013, 37(11): 1519-1522.
[3]	吴晨辰 , 张晓梅 . 放射性131I在Graves病治疗中的应用进展. 蚌埠医学院学报, 2014, 38(5): 697-700.
[4]	金进 . 泼尼松联合甲巯咪唑与单纯口服甲巯咪唑治疗Graves病疗效比较. 蚌埠医学院学报, 2012, 36(6): 699-701.
[5]	申勇 , 袁媛 , 孙伟莉 , 陶健 , 何娟娟 , 李卫鹏 . Graves病131I治疗中的细胞因子变化. 蚌埠医学院学报, 2014, 38(6): 795-797.
[6]	吴凤 , 李阳 , 张艳 , 成立 , 孙医学 . 彩色脉搏波技术定量评价Graves病早期颈动脉结构及功能变化. 蚌埠医学院学报, 2020, 45(2): 235-237. doi: 10.13898/j.cnki.issn.1000-2200.2020.02.027
[7]	查秀婧 , 毕娅欣 . 细胞毒性T淋巴细胞相关抗原-4基因多态性与Graves病复发的相关性研究. 蚌埠医学院学报, 2015, 40(1): 14-16. doi: 10.13898/j.cnki.issn.1000-2200.2015.01.005
[8]	龚莉 , 黄莹芝 , 冯锋 , 常琳 , 王敏 . Graves病合并重症肌无力1例报道并文献复习. 蚌埠医学院学报, 2013, 37(1): 77-79.
[9]	胡永全 , 郭道华 , 刘恒超 , 申勇 , 李卫鹏 . ¹³¹I治疗Graves病合并白细胞减少的临床评价. 蚌埠医学院学报, 2014, 39(11): 1476-1478.
[10]	李自生 , 朱立亿 , 周健 . Graves病患者促甲状腺素受体抗体检测的临床应用价值. 蚌埠医学院学报, 2006, 31(3): 300-301.
[11]	明希希 , 王涛 . 维生素D受体在系统性红斑狼疮中的免疫调节作用研究进展. 蚌埠医学院学报, 2023, 48(5): 698-701. doi: 10.13898/j.cnki.issn.1000-2200.2023.05.034
[12]	唐样 , 王宜君 , 王璐瑶 , 宋雪 . 通过抑制氧化应激损伤治疗炎症性肠病的前景展望. 蚌埠医学院学报, 2024, 49(1): 137-141. doi: 10.13898/j.cnki.issn.1000-2200.2024.01.031
[13]	冯敏 , 董淮富 . S100B蛋白在新生儿缺氧缺血性脑病诊断和预后判断中的研究进展. 蚌埠医学院学报, 2012, 36(11): 1396-1399.
[14]	王圣应 . 分化型甲状腺癌的外科治疗进展. 蚌埠医学院学报, 2004, 29(6): 571-573.
[15]	汪运生 , 石建华 , 项平 . 甲状腺乳头状癌中NTRK1基因重排的研究进展. 蚌埠医学院学报, 2011, 36(2): 213-216.
[16]	孙佩璇 , 孙医学 . 超声弹性对比指数在甲状腺疾病中的应用及其影响因素研究进展. 蚌埠医学院学报, 2018, 43(2): 276-279. doi: 10.13898/j.cnki.issn.1000-2200.2018.02.043
[17]	曲真真 , 石建华 , 汪万英 . nm23和Bcl-2基因在甲状腺肿瘤中的研究进展. 蚌埠医学院学报, 2009, 34(3): 267-269.
[18]	王春 , 石建华 , 汪万英 . p53和p16基因在甲状腺癌中的研究进展. 蚌埠医学院学报, 2009, 34(5): 455-457.
[19]	徐颖 , 石建华 , 项平 . 胰岛素降解酶基因与2型糖尿病的关系研究进展. 蚌埠医学院学报, 2010, 35(4): 426-429.
[20]	赵瑞萍 , 陈卫东 . 甘露糖结合凝集素、C反应蛋白与糖尿病肾病关系的研究进展. 蚌埠医学院学报, 2016, 41(1): 129-132. doi: 10.13898/j.cnki.issn.1000-2200.2016.01.042

点击查看大图

计量

文章访问数: 3460
HTML全文浏览量: 395
PDF下载量: 206
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

人促甲状腺激素受体及其抗体与Graves病关系研究进展

作者简介: 王冉(1982－ ),女,硕士研究生.

计量

人促甲状腺激素受体及其抗体与Graves病关系研究进展

作者简介: 王冉(1982－ ),女,硕士研究生.

全文HTML

目录

留言板

人促甲状腺激素受体及其抗体与Graves病关系研究进展

作者简介: 王冉(1982－ ),女,硕士研究生.

计量

出版历程

人促甲状腺激素受体及其抗体与Graves病关系研究进展

作者简介: 王冉(1982－ ),女,硕士研究生.

全文HTML

目录